MicroRNA-145 as ideal biomarker for the diagnosis of various carcinomas

Tumor Biology

Volumn 36, Issue 4, 2015, Pages 2641-2649

  Hou, Yanmei ^a   Wang, Xiang ^a   Chen, Yan ^a   Mu, Shengqun ^a  

^a Jinan Women and Children Hospital   (China)

Author keywords

Cancer; Diagnostic value; Meta analysis; MicroRNA 145

Indexed keywords

MICRORNA; MIRN145 MICRORNA, HUMAN; TUMOR MARKER;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; DIAGNOSTIC USE; HUMAN; META ANALYSIS; NEOPLASMS; PATHOLOGY;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; HUMANS; MICRORNAS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84936768476     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2886-9     Document Type: Article

References (44)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2010;127:2893–917.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
4. Leone G, Fianchi L, Pagano L, Voso MT. Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact. 2010;184:39–45.
5. Morse MA, Stoner GD. Cancer chemoprevention: principles and prospects. Carcinogenesis. 1993;14:1737–46.
6. Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev. 2012;32:326–48.
7. Mazzone P, Jain P, Arroliga AC, Matthay RA. Bronchoscopy and needle biopsy techniques for diagnosis and staging of lung cancer. Clin Chest Med. 2002;23:137–58. ix.
8. Gohagan JK, Marcus PM, Fagerstrom RM, Pinsky PF, Kramer BS, et al. Final results of the lung screening study, a randomized feasibility study of spiral ct versus chest x-ray screening for lung cancer. Lung Cancer. 2005;47:9–15.
9. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
10. Oken MM, Marcus PM, Hu P, Beck TM, Hocking W, et al. Baseline chest radiograph for lung cancer detection in the randomized prostate, lung, colorectal and ovarian cancer screening trial. J Natl Cancer Inst. 2005;97:1832–9.
11. Taplin S, Abraham L, Barlow WE, Fenton JJ, Berns EA, et al. Mammography facility characteristics associated with interpretive accuracy of screening mammography. J Natl Cancer Inst. 2008;100:876–87.
12. Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C, et al. Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. Gastroenterology. 2014;146:709–17.
13. Takahashi S, Hirayama M, Kuroiwa G, Kawano Y, Takada K, et al. Diagnostic validity of CT gastrography versus gastroscopy for primary lesions in gastric cancer: evaluating the response to chemotherapy, a retrospective analysis. Gastric Cancer. 2013;16:543–8.
14. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, et al. Survival of patients with stage i lung cancer detected on ct screening. N Engl J Med. 2006;355:1763–71.
15. Mascalchi M, Belli G, Zappa M, Picozzi G, Falchini M, et al. Risk-benefit analysis of x-ray exposure associated with lung cancer screening in the Italung-ct trial. AJR Am J Roentgenol. 2006;187:421–9.
16. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006;24:971–83.
17. Etzioni R, Kooperberg C, Pepe M, Smith R, Gann PH. Combining biomarkers to detect disease with application to prostate cancer. Biostatistics. 2003;4:523–38.
18. Fiorucci G, Chiantore MV, Mangino G, Percario ZA, Affabris E, et al. Cancer regulator microRNA: potential relevance in diagnosis, prognosis and treatment of cancer. Curr Med Chem. 2012;19:461–74.
19. Anindo MI, Yaqinuddin A. Insights into the potential use of microRNAs as biomarker in cancer. Int J Surg. 2012;10:443–9.
20. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer. 2010;9:306.
21. Madhavan D, Cuk K, Burwinkel B, Yang R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet. 2013;4:116.
22. Weiland M, Gao XH, Zhou L, Mi QS. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol. 2012;9:850–9.
23. Fabbri M. MiRNAs as molecular biomarkers of cancer. Expert Rev Mol Diagn. 2010;10:435–44.
24. George GP, Mittal RD. MicroRNAs: potential biomarkers in cancer. Indian J Clin Biochem. 2010;25:4–14.
25. Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin Chem. 2009;55:623–31.
26. Yun SJ, Jeong P, Kim WT, Kim TH, Lee YS, et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol. 2012;41:1871–8.
27. Mar-Aguilar F, Mendoza-Ramirez JA, Malagon-Santiago I, Espino-Silva PK, Santuario-Facio SK, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers. 2013;34:163–9.
28. Tang D, Shen Y, Wang M, Yang R, Wang Z, et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013;22:540–8.
29. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889–97.
30. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer. 2009;125:345–52.
31. Luo X, Stock C, Burwinkel B, Brenner H. Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS ONE. 2013;8:e62880.
32. Shigehara K, Yokomuro S, Ishibashi O, Mizuguchi Y, Arima Y, et al. Real-time PCR-based analysis of the human bile microRNAome identifies mir-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One. 2011;6:e23584.
33. Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, et al. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer. 2012;130:611–21.
34. Zaravinos A, Radojicic J, Lambrou GI, Volanis D, Delakas D, et al. Expression of miRNAs involved in angiogenesis, tumor cell proliferation, tumor suppressor inhibition, epithelial-mesenchymal transition and activation of metastasis in bladder cancer. J Urol. 2012;188:615–23.
35. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.
36. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58:882–93.
37. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–35.
38. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
39. Jackson D, White IR, Thompson SG. Extending DerSimonian and Laird’s methodology to perform multivariate random effects meta-analyses. Stat Med. 2010;29:1282–97.
40. Paranjape T, Slack FJ, Weidhaas JB. MicroRNAs: tools for cancer diagnostics. Gut. 2009;58:1546–54.
41. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007;6:60.
42. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
43. Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.
44. Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F. A likelihood ratio approach to meta-analysis of diagnostic studies. J Med Screen. 2003;10:47–51.